erlotinib gel (SGT-210) / Sol-Gel - LARVOL DELTA

Final OS results from RELAY (1L erlotinib +/- ramucirumab in #EGFR NSCLC) now @JTOonline. FDA approved based on PFS benefit. After 45m f/u, no OS difference (51.1m vs 46.0m, HR 0.98). Over 80% received 2L therapy (osimertinib use similar in both arms).

Tackling Stage III EGFR Mutation-Positive Lung Cancer: Do We Really Know How? (YouTube) - "This JCO Podcast provides observations and commentary on the JCO article 'Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment for Stage IIIA-N2 EGFR-Mutant NSCLC (EMERGING-CTONG 1103): A Randomized Phase II Study'...My name is Tony Mok..."

Video

Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ. (PubMed, Nanomedicine (Lond)) - " In a comparative assessment against plain ERL, ERL@TG displayed enhanced efficacy against MCF-7 cell lines, reflected in considerably lower IC50 values with an enhanced safety profile. Optimized ERL@TG was identified as a promising avenue for addressing ductal carcinoma in situ breast cancer."

Journal • Breast Cancer • Oncology • Solid Tumor